MUC1/HER2/neu peptide-based immunotherapeutic vaccines for breast adenocarcinomas. This is an ASCO Meeting Abstract from the 2011 ASCO Annual Meeting I. This abstract does not include a full text ...
Repertoire® Immune Medicines, a biotechnology company pioneering the discovery and development of programmable T cell-targeted immune medicines, today announced that the U.S. Food and Drug ...
FDA fast track designation enables increased regulatory interaction and potential rolling BLA review for RPTR-1.201 in ...
The FDA has granted Fast Track Designation to RPTR-1-201 for unresectable or metastatic triple-negative breast cancer after ...
Effect of RNAi-based β-catenin inhibition on immunosuppressive Wnt-activated tumors in combination with IDOi/PD-1 immunotherapy. There was a systematic decrease of CD3e or CD3z expression at the RNA ...
Treatment with anti-CD19 bispecific T-cell engager and CAR T therapies can lead to T-cell exhaustion and treatment failure. Novartis AG’s first-in-class anti-CD19, anti-CD3 and anti-CD2 IgG-like ...
Immunocore’s tebentafusp has improved overall survival in metastatic uveal melanoma patients. The phase 3 success marks a landmark for the use of T-cell receptor (TCR) therapeutics and bispecifics in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results